Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional

None.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Huml, Raymond A. (Συγγραφέας)
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: New York, NY : Springer New York : Imprint: Springer, 2012.
Σειρά:SpringerBriefs in Pharmaceutical Science & Drug Development,
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 03206nam a22004455i 4500
001 978-1-4614-3682-9
003 DE-He213
005 20130726225945.0
007 cr nn 008mamaa
008 120614s2012 xxu| s |||| 0|eng d
020 |a 9781461436829  |9 978-1-4614-3682-9 
024 7 |a 10.1007/978-1-4614-3682-9  |2 doi 
040 |d GrThAP 
050 4 |a RS380 
050 4 |a RS190-210 
072 7 |a TDCW  |2 bicssc 
072 7 |a MED072000  |2 bisacsh 
082 0 4 |a 615.19  |2 23 
100 1 |a Huml, Raymond A.  |e author. 
245 1 0 |a Pharmaceutical Competitive Intelligence for the Regulatory Affairs Professional  |h [electronic resource] /  |c by Raymond A. Huml. 
264 1 |a New York, NY :  |b Springer New York :  |b Imprint: Springer,  |c 2012. 
300 |a XV, 82 p. 4 illus., 3 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a SpringerBriefs in Pharmaceutical Science & Drug Development,  |x 1864-8118 
505 0 |a This Brief defines competitive intelligence (CI) as a tool for making investment decisions within the pharmaceutical industry.  It provides an overview of processes that the regulatory affairs professional must take into account when evaluating data impacting product-based risk evaluations. These apply particularly to evaluations that focus on outputs such as regulatory approval, or the commercial impact of product labeling on the sales forecast over a limited timeframe. The Brief also provides an overview of intellectual property assessment that can impact a product’s lifespan on the market due to patent protection itself (or loss of patent protection) or via regulatory exclusivity. Case examples are discussed to illustrate the importance of keeping up with the ever-changing regulations, and how to interpret them in the context of CI. In addition, there is a section on virtual data rooms (VDRs) which currently function as the cornerstone of due diligence investigations. While aimed primarily at regulatory affairs professionals in the United States, this publication provides a useful adjunct for other pharmaceutical executives, especially those new to product-based investments, and regulatory affairs professionals in other regions. Table of contents: Introduction to Competitive Intelligence -- Overall Perspective of Due Diligence Investigations and Processes -- The Regulatory Functional Review – Primary Roles -- The On-Site Due Diligence/Data Room Meeting and Interactions with other Functional Area Experts -- Intellectual Property -- The Final Report -- Competitive Intelligence Summary. 
520 |a None. 
650 0 |a Medicine. 
650 0 |a Pharmaceutical technology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Pharmaceutical Sciences/Technology. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9781461436812 
830 0 |a SpringerBriefs in Pharmaceutical Science & Drug Development,  |x 1864-8118 
856 4 0 |u http://dx.doi.org/10.1007/978-1-4614-3682-9  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)